FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 113 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 469.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $844,000 | +68.5% | 22,408 | -23.8% | 0.00% | – |
| Q4 2020 | $501,000 | +682.8% | 29,395 | +115.8% | 0.00% | – |
| Q3 2020 | $64,000 | -14.7% | 13,620 | +10.5% | 0.00% | – |
| Q2 2020 | $75,000 | +200.0% | 12,328 | +14.2% | 0.00% | – |
| Q1 2020 | $25,000 | -52.8% | 10,795 | -9.3% | 0.00% | – |
| Q4 2019 | $53,000 | -56.9% | 11,903 | -62.8% | 0.00% | – |
| Q3 2019 | $123,000 | -89.5% | 31,997 | -83.5% | 0.00% | -100.0% |
| Q2 2019 | $1,168,000 | +268.5% | 194,041 | +715.4% | 0.00% | – |
| Q1 2019 | $317,000 | -70.7% | 23,796 | -79.6% | 0.00% | -100.0% |
| Q4 2018 | $1,081,000 | -79.2% | 116,401 | -68.9% | 0.00% | -50.0% |
| Q3 2018 | $5,206,000 | -32.5% | 374,152 | -23.3% | 0.00% | 0.0% |
| Q2 2018 | $7,709,000 | +38.9% | 487,693 | +50.9% | 0.00% | -33.3% |
| Q1 2018 | $5,552,000 | +80.6% | 323,245 | +130.4% | 0.00% | +50.0% |
| Q4 2017 | $3,074,000 | -33.3% | 140,323 | +24.5% | 0.00% | -33.3% |
| Q3 2017 | $4,608,000 | -52.6% | 112,668 | -65.1% | 0.00% | -57.1% |
| Q2 2017 | $9,727,000 | -17.0% | 323,098 | -0.4% | 0.01% | -22.2% |
| Q1 2017 | $11,723,000 | +152.7% | 324,372 | +250.2% | 0.01% | +125.0% |
| Q4 2016 | $4,640,000 | -10.4% | 92,634 | -6.2% | 0.00% | 0.0% |
| Q3 2016 | $5,181,000 | -9.7% | 98,765 | -28.8% | 0.00% | 0.0% |
| Q2 2016 | $5,738,000 | +50.3% | 138,805 | +47.6% | 0.00% | +33.3% |
| Q1 2016 | $3,817,000 | -41.0% | 94,022 | -39.7% | 0.00% | -25.0% |
| Q4 2015 | $6,472,000 | +376.9% | 156,015 | +76.7% | 0.00% | +300.0% |
| Q3 2015 | $1,357,000 | -37.4% | 88,275 | +1.0% | 0.00% | 0.0% |
| Q2 2015 | $2,169,000 | +588.6% | 87,399 | +532.1% | 0.00% | – |
| Q1 2015 | $315,000 | -50.8% | 13,827 | -41.9% | 0.00% | – |
| Q4 2014 | $640,000 | +603.3% | 23,801 | +201.4% | 0.00% | – |
| Q3 2014 | $91,000 | -3.2% | 7,897 | +29.8% | 0.00% | – |
| Q2 2014 | $94,000 | -38.2% | 6,084 | -21.5% | 0.00% | – |
| Q1 2014 | $152,000 | -82.7% | 7,749 | -85.2% | 0.00% | -100.0% |
| Q4 2013 | $880,000 | – | 52,498 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |